博晖创新：控股孙公司联合获得冻干人用狂犬病疫苗临床试验批准通知书

Core Viewpoint - The announcement indicates that the company’s subsidiary, Bohui Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for a lyophilized rabies vaccine, which is intended to stimulate immune response against rabies [1] Group 1: Company Developments - Bohui Innovation announced that its subsidiary has jointly applied for a rabies vaccine with Beijing Baihui Biotechnology Co., Ltd. [1] - The rabies vaccine is designed to prevent rabies by using purified rabies virus antigens to stimulate the immune response [1] - The approval for clinical trials is a significant step in the vaccine development process, although the company notes that drug development involves high investment, high risk, and long cycles [1] Group 2: Market Context - Currently, the domestic market for human rabies vaccines includes manufacturers such as Chengdu Kanghua Biological Products Co., Ltd. and Beijing Minhui Biotechnology Co., Ltd. [1] - The company acknowledges potential risks associated with drug development, including clinical trial outcomes not meeting expectations and delays in regulatory approvals or market entry [1] - The approval for the clinical trial is not expected to have a significant impact on the company's short-term performance [1]